UroGen Pharma (URGN) Change in Receivables (2017 - 2026)
UroGen Pharma's (URGN) quarterly Change in Receivables came in at $22.3 million in Q1 2026, up 3462.95% YoY from $626727.5 in Q1 2025, and up 66.9% on a QoQ basis from $13.4 million in Q4 2025.
UroGen Pharma (URGN) Change in Receivables (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 9 years of Change in Receivables data on file, last reported at $22.3 million in Q1 2026.
- Quarterly Change in Receivables rose 3462.95% year-over-year to $22.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.8 million (up 552.81% YoY) and the FY2025 annual result came in at $12.8 million, up 163.02% from the prior year.
- Change in Receivables advanced to $22.3 million in Q1 2026, from $13.4 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $22.3 million in Q1 2026 to a low of -$2.7 million in Q3 2023.
- A 5-year average of $2.6 million and a median of $54000.0 in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2024 — Change in Receivables sank 509.0% — and 2026, when it soared 3462.95%.
- Tracing URGN's Change in Receivables over 5 years: stood at $3.3 million in 2022, then declined by 20.73% to $2.6 million in 2023, then sank by 196.3% to -$2.5 million in 2024, then soared by 635.16% to $13.4 million in 2025, then surged by 66.9% to $22.3 million in 2026.
- The last three Change in Receivables figures came in at $22.3 million (Q1 2026), $13.4 million (Q4 2025), and $54000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 33.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.35 Mn |
| Jun 30, 2026 | 33.35 Mn |
| Mar 31, 2026 | 22.33 Mn |
| Mar 31, 2026 | 22.33 Mn |
| Dec 31, 2025 | 13.38 Mn |
| Dec 31, 2025 | 13.38 Mn |
| Sep 30, 2025 | 54,000.00 |
| Sep 30, 2025 | 54,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | -664,000.00 |
| Mar 31, 2025 | -664,000.00 |
| Dec 31, 2024 | -2.50 Mn |
| Dec 31, 2024 | -2.50 Mn |
| Sep 30, 2024 | 5.39 Mn |
| Sep 30, 2024 | 5.39 Mn |
| Jun 30, 2024 | 3.26 Mn |
| Jun 30, 2024 | 3.26 Mn |
| Mar 31, 2024 | -1.29 Mn |
| Mar 31, 2024 | -1.29 Mn |